Sarepta TherapeuticsSRPT
SRPT
0
Funds holding %
of 6,759 funds
0
Analysts bullish %
of 14 analysts
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
152% more first-time investments, than exits
New positions opened: 121 | Existing positions closed: 48
124% more call options, than puts
Call options by funds: $729M | Put options by funds: $325M
41% more repeat investments, than reductions
Existing positions increased: 178 | Existing positions reduced: 126
33% more capital invested
Capital invested by funds: $10.8B [Q1] → $14.4B (+$3.57B) [Q2]
18% more funds holding
Funds holding: 407 [Q1] → 480 (+73) [Q2]
7.29% more ownership
Funds ownership: 89.02% [Q1] → 96.31% (+7.29%) [Q2]
7% more funds holding in top 10
Funds holding in top 10: 15 [Q1] → 16 (+1) [Q2]
Research analyst outlook
14 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$150
33%
upside
Avg. target
$176
56%
upside
High target
$205
82%
upside
14 analyst ratings
13 positive
93%
1 neutral
7%
0 negative
0%
Guggenheim Whitney Ijem 37% 1-year accuracy 13 / 35 met price target | 33%upside $150 | Buy Maintained | 7 Nov 2024 |
Baird Brian Skorney 45% 1-year accuracy 9 / 20 met price target | 72%upside $193 | Outperform Maintained | 7 Nov 2024 |
Evercore ISI Group Gavin Clark-Gartner 50% 1-year accuracy 1 / 2 met price target | 51%upside $170 | Outperform Maintained | 7 Nov 2024 |
Cantor Fitzgerald Kristen Kluska 59% 1-year accuracy 62 / 105 met price target | 48%upside $167 | Overweight Upgraded | 7 Nov 2024 |
Needham Gil Blum 42% 1-year accuracy 65 / 156 met price target | 82%upside $205 | Buy Reiterated | 7 Nov 2024 |
Financial journalist opinion
Based on 9 articles about SRPT published over the past 30 days
Charts implemented using Lightweight Charts™